TP53 and neoplasm: In these cases, the tumour section used for IHC was different from the tumour tissue used for TP53 sequencing; therefore, intratumoral heterogeneity of TP53 mutations may result in a discrepancy between p53 status determined by IHC and the TP53 sequencing results.